Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.79USD
−163.07 MUSD
45.71 M
About ABIVAX
Sector
CEO
Marc M. P. de Garidel
Headquarters
Paris
Website
Employees (FY)
61
Founded
2013
ISIN
FR0012333284
FIGI
BBG00DX9WMZ3
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of AAVXF is 15.15 USD — it has increased by 38.36% in the past 24 hours. Watch Abivax SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Abivax SA stocks are traded under the ticker AAVXF.
We've gathered analysts' opinions on Abivax SA future price: according to them, AAVXF price has a max estimate of 50.06 USD and a min estimate of 15.98 USD. Watch AAVXF chart and read a more detailed Abivax SA stock forecast: see what analysts think of Abivax SA and suggest that you do with its stocks.
AAVXF reached its all-time high on Jan 4, 2021 with the price of 43.97 USD, and its all-time low was 5.79 USD and was reached on Dec 14, 2022. View more price dynamics on AAVXF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
AAVXF stock is 28.00% volatile and has beta coefficient of 1.26. Track Abivax SA stock price on the chart and check out the list of the most volatile stocks — is Abivax SA there?
Today Abivax SA has the market capitalization of 883.33 M, it has increased by 1.55% over the last week.
Yes, you can track Abivax SA financials in yearly and quarterly reports right on TradingView.
Abivax SA is going to release the next earnings report on Sep 9, 2024. Keep track of upcoming events with our Earnings Calendar.
AAVXF earnings for the last quarter are −2.06 USD per share, whereas the estimation was −0.94 USD resulting in a −119.41% surprise. The estimated earnings for the next quarter are −1.68 USD per share. See more details about Abivax SA earnings.
Abivax SA revenue for the last quarter amounts to 2.65 M USD despite the estimated figure of 2.54 M USD. In the next quarter revenue is expected to reach 2.55 M USD.
AAVXF net income for the last quarter is −105.72 M USD, while the quarter before that showed −56.67 M USD of net income which accounts for −86.57% change. Track more Abivax SA financial stats to get the full picture.
No, AAVXF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 18, 2024, the company has 61.00 employees. See our rating of the largest employees — is Abivax SA on this list?
Like other stocks, AAVXF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Abivax SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Abivax SA technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Abivax SA stock shows the neutral signal. See more of Abivax SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.